Methotrexate in a psoriatic arthritis patient
Abstract
The case report a psoriatic arthritis patient (disfiguring form, high laboratory values, changes of the skin and nails) treated with methotrexate. The drug demonstrated high efficacy resulting in stable sustained remission of articular syndrome, documented both by clinical and laboratory parameters, decreased cutaneous syndromes, improved functional activity and better life quality.
About the Authors
K. V. Aleksanyan
I.M. Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
Karina Aleksanyan, pediatrician at the University Child Clinic Hospital
19, B. Pirogovskaya str., Moscow, 119435
E. S. Zholobova
I.M. Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
Doctor of Medical Sciences, professor at the Department of Childhood Diseases
S. N. Chebysheva
I.M. Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
Candidate of Medical Sciences, Associate Professor at the Department of Childhood Diseases
A. V. Meleshkina
I.M. Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
Candidate of Medical Sciences, Associate Professor at the Department of Childhood Diseases
M. N. Nikolaeva
University Child Clinic Hospital, Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
Rheumatologist
References
1. Bunchuk N.V., Badokin V.I., Korotaeva T.V. Psoriatic arthritis. In: Nasonov E.L., Nasonova V.A. (eds). Rheumatology national leadership. Moscow: GEOTARMedia; 2008: 355–366 (in Russian).
2. Chebysheva S.N., Geppe N.A., Podchernyaeva N.S., Lyskina G.A. (eds). Psoriatic arthritis in pediatric rheumatology Guide. Moscow: GEOTAR-Media; 2011: 285–299 (in Russian).
3. Chebysheva S.N., Zholobova E.S., Geppe N.A., Meleshkina A.V. Diagnosis, clinic and therapy of psoriatic arthritis in children. Doctor Ru. 2012; 9(77 ): 28–33 (in Russian).
4. Veale D., Ritchlin С., FitzGerald О. Immunopathology of psoriasis and psoriatic arthritis. Ann. Rheum. Dis. 2005; 64(Suppl. II): 26–29.
5. Cassidy J.T. Outcomes research in the therapeutic use of methotrexate in children with chronic peripheral arthritis. J. Pediatr. 1998; 133: 179–180.
6. Tambic-Bukovac L., Malcic I., Prohic A. Personal experience with methotrexate in the treatment of idiopathic juvenile arthritis. Rheumatism. 2002; 49(1): 20–24.
7. Tukova J., Chladek J., Nemcova D. et al. Methotrexate bioavailability after oral and subcutaneous administration in children with juvenile idiopathic arthritis. Clin. Exp. Rheumatol. 2009; 27(6): 1047–1053.
8. Alsufyani K., Ortiz-Alvarez O., Cabral D.A. et al. The role of subcutaneous administration of methotrexate in children with juvenile idiopathic arthritis who have failed oral methotrexate. J. Rheumatol. 2004; 31(1): 179–182.
9. Klein A., Kaul I., Foeldvari I., Ganser G., Urban A., Horneff G. Efficacy and safety of oral and parenteral methotrexate therapy in children with juvenile idiopathic arthritis: an observational study with patients from the German Methotrexate Registry. Arthritis Care Res. (Hoboken). 2012; 64(9): 1349–1356.
Review
Views: 31
Email this article 